WeVote
Log In

Bill

Bill

SB 1287

Relating to the effect of certain reductions in a health benefit plan enrollee's out-of-pocket expenses for prescription drugs that are essential health benefits on the enrollee's cost-sharing requirements.

89th Legislature (2025) Introduced by Bryan Hughes

SB 1287 clarifies how prescription drug cost reductions affect enrollees' deductible and out-of-pocket maximum calculations under Texas health benefit plans.

Referred to Health & Human Services
#contractors&subcontractors(s2563) #insurance--health&accident(i0422) #medicine&prescriptiondrugs(s7338) #pharmacybenefitmanagers(s0648)
0
WeVote Research Nonpartisan
Bill Summary · SB 1287

Legislative bill overview

SB 1287 addresses how reductions in out-of-pocket prescription drug costs for essential health benefits should affect overall cost-sharing requirements for health plan enrollees in Texas. The bill appears to clarify or modify the treatment of drug cost assistance programs, copay coupons, or similar financial aid when calculating an enrollee's deductible and maximum out-of-pocket expenses.

Why is this important

Prescription drug costs represent a significant portion of healthcare expenses for many Texans, and how these costs are counted toward deductibles can substantially impact enrollee financial obligations. The bill's outcome could either expand access to affordable medications or create accounting mechanisms that affect insurance plan pricing and coverage structures across the state.

Potential points of contention

  • Manufacturer assistance programs vs. plan costs: Determining whether third-party drug cost reductions (manufacturer coupons, copay assistance) should count toward an enrollee's out-of-pocket maximum could shift financial burden between insurers, manufacturers, and patients
  • Insurance premium implications: Clarifying cost-sharing rules may require insurers to restructure premium pricing, potentially affecting affordability for all plan members
  • Regulatory scope: The bill's definition of "certain reductions" and which programs qualify could create implementation ambiguity and regulatory enforcement challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.